IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
VANCOUVER, Canada and NEW YORK, NY, USA I February 21, 2024 I Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de novo generative AI foundation model. Given a target structure, Absci uses this model to designate a specific epitope of interest, allowing for the engineering of epitope-specific antibodies to access novel biology. Absci then uses its AI lead optimization models to further engineer candidates to have an optimal clinical development profile.
Absci presented early preclinical data on ABS-101 in January, with three advanced leads showing properties consistent with a potentially superior product profile, including demonstrated high affinity, high potency, favorable developability, and extended half-life. Absci used its de novo AI model to design ABS-101 toward a specific epitope with the objective for superior potency and lower immunogenicity. This target product profile, combined with anticipated high bioavailability, could ultimately improve patient experience with easier, less frequent dosing. Following further confirmatory PK studies in February, Absci selected a development candidate to advance into IND-enabling studies.
“The initiation of IND-enabling studies for ABS-101 represents a major milestone for Absci,” said Sean McClain, Founder and CEO of Absci. “The progress we have made on this program demonstrates the ability of our platform to create a differentiated antibody drug candidate in less than half the time of industry standards, as we expect to submit our IND approximately two years after beginning this program. This achievement illustrates the power of using generative AI to improve the drug discovery process to bring better medicines to patients, faster.”
ABS-101 is Absci’s lead asset from its internal AI Drug Creation asset pipeline focused on cytokine biology. The initiation of IND-enabling studies represents an important step forward in Absci’s efforts to bring potentially transformative therapeutics to patients, faster.
Absci expects to submit an IND for ABS-101 in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
SOURCE: Absci
Post Views: 580
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after
VANCOUVER, Canada and NEW YORK, NY, USA I February 21, 2024 I Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de novo generative AI foundation model. Given a target structure, Absci uses this model to designate a specific epitope of interest, allowing for the engineering of epitope-specific antibodies to access novel biology. Absci then uses its AI lead optimization models to further engineer candidates to have an optimal clinical development profile.
Absci presented early preclinical data on ABS-101 in January, with three advanced leads showing properties consistent with a potentially superior product profile, including demonstrated high affinity, high potency, favorable developability, and extended half-life. Absci used its de novo AI model to design ABS-101 toward a specific epitope with the objective for superior potency and lower immunogenicity. This target product profile, combined with anticipated high bioavailability, could ultimately improve patient experience with easier, less frequent dosing. Following further confirmatory PK studies in February, Absci selected a development candidate to advance into IND-enabling studies.
“The initiation of IND-enabling studies for ABS-101 represents a major milestone for Absci,” said Sean McClain, Founder and CEO of Absci. “The progress we have made on this program demonstrates the ability of our platform to create a differentiated antibody drug candidate in less than half the time of industry standards, as we expect to submit our IND approximately two years after beginning this program. This achievement illustrates the power of using generative AI to improve the drug discovery process to bring better medicines to patients, faster.”
ABS-101 is Absci’s lead asset from its internal AI Drug Creation asset pipeline focused on cytokine biology. The initiation of IND-enabling studies represents an important step forward in Absci’s efforts to bring potentially transformative therapeutics to patients, faster.
Absci expects to submit an IND for ABS-101 in the first quarter of 2025. Subject to clearance of the IND, Absci expects to initiate Phase 1 studies for this program shortly thereafter.
About Absci
Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.
Availability of Other Information about Absci
Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
SOURCE: Absci
Post Views: 580
